Gilead reports proof-of-concept d ata for GS-6207, a First-in-Class Capsid Inhibitor, in P
Gilead reported the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load. July 22, 2019